Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Gastrointestinal Oncology|July 17, 2025
Liver transplantation in a patient with metastatic hepatocellular carcinoma after downstaging with single-agent immunotherapy: the first case reportAngelo Pirozzi, Celine Hoyek, Oluseyi Abidoye, et al.
JCO Precision Oncology|April 9, 2026
Bespoke Circulating Tumor DNA Testing for Diagnostic Resolution, Disease Surveillance, and Treatment Monitoring in Hepatopancreatobiliary Malignancies: A Real-World ExperienceOluseyi Abidoye, Angelo Pirozzi, Naohiro Okano, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 29, 2025
Evaluating third-line therapies in refractory metastatic colorectal cancer: a systematic review and network meta-analysisCeline Hoyek, Syed Arsalan Ahmed Naqvi, Oudai Sahvan, et al.
Japanese Journal of Clinical Oncology|April 2, 2025
Systemic therapy for pretreated advanced biliary tract cancer: past developments and recent advancesNaohiro Okano, Angelo Pirozzi, Oluseyi Abidoye, et al.
Journal of Gastroenterology|May 25, 2026
Clinico-molecular characteristics and enhanced efficacy of immune checkpoint inhibitors in TP53-mutated advanced biliary tract cancerTaro Shibuki, Celine Hoyek, Ryne Ramaker, et al.
Liver Cancer|December 24, 2025
Vessels That Encapsulate Tumor Cluster+ Unresectable Hepatocellular Carcinomas Benefit of Antiangiogenic TherapyCamilla De Carlo, Reha Akpinar, Barbara Durante, et al.
NPJ Precision Oncology|May 5, 2026
Survival outcomes with matched targeted therapy in advanced biliary tract cancer: a large global cohort analysisBinbin Zheng-Lin, Taro Shibuki, Heidi E Kosiorek, et al.
Cancers|March 28, 2025
Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter StudyChristian Möhring, Moritz Berger, Farsaneh Sadeghlar, et al.
JHEP Reports : Innovation in Hepatology|January 29, 2025
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumabMeng Wu, Claudia A M Fulgenzi, Antonio D'Alessio, et al.
Journal of Hepatocellular Carcinoma|April 9, 2025
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and BevacizumabBernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, et al.
Pageof 3